Skyrizi

Skyrizi is the brand name for risankizumab, a human monoclonal antibody that targets the p19 subunit of interleukin-23 (IL-23). By inhibiting IL-23, Skyrizi aims to reduce inflammatory signaling involved in certain autoimmune diseases. It is developed and marketed by AbbVie.

In many markets, Skyrizi is indicated for adults with moderate to severe plaque psoriasis who are candidates for systemic therapy or phototherapy. It has also been approved for adults with active Crohn's disease in regions where regulatory oversight supports such use. The scope of approved indications can vary by country and over time as new data and labels are issued.

Mechanistically, Skyrizi blocks IL-23 signaling, a pathway thought to drive the maintenance of inflammatory processes in the skin and gastrointestinal tract. This selective inhibition of the IL-23/Th17 axis distinguishes it from agents that target broader immune pathways.

Administration and dosing are by subcutaneous injection. Specific dosing schedules depend on the indication and region, but regimens generally involve an initial loading phase followed by maintenance injections at intervals of several weeks to months. The long dosing interval reflects the drug’s pharmacokinetic properties and aims to balance efficacy with patient convenience.

Common adverse events reported with Skyrizi include infections of the upper respiratory tract, headaches, fatigue, and injection-site reactions. Serious adverse events may occur, including increased susceptibility to infections and potential hypersensitivity. As with all biologics, patients should be monitored for safety, and use should be guided by a healthcare professional.